We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+25.81%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$241M
AUM Growth
+$50.3M
Cap. Flow
+$11.8M
Cap. Flow %
4.88%
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17

Top Buys

Rank Stock Value
1
BEPC icon
Brookfield Renewable
BEPC
+$1.51M
2
WES icon
Western Midstream Partners
WES
+$926K
3
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
+$707K
4
DK icon
Delek US
DK
+$681K
5
CVI icon
CVR Energy
CVI
+$669K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.61M
2
AIMT
Aimmune Therapeutics
AIMT
+$1.13M
3
AIV
Aimco
AIV
+$1.1M
4
VIV icon
Telefônica Brasil
VIV
+$1.01M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$988K

Sector Composition

Rank Sector Weight
1 Healthcare 29.53%
2 Real Estate 18.96%
3 Energy 16.61%
4 Materials 11.31%
5 Utilities 7.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCRB icon
226
Seres Therapeutics
MCRB
$45M
$291K 0.12%
+595
New +$348K
RYTM icon
227
Rhythm Pharmaceuticals
RYTM
$7.31B
$291K 0.12%
9,772
-5,612
-36% -$143K
CCXI
228
DELISTED
ChemoCentryx, Inc.
CCXI
$291K 0.12%
4,694
-38
-0.8% -$2.18K
CYTK icon
229
Cytokinetics
CYTK
$10.6B
$289K 0.12%
13,889
-528
-4% -$9.65K
RCKT icon
230
Rocket Pharmaceuticals
RCKT
$343M
$289K 0.12%
5,261
-11,734
-69% -$428K
BLUE
231
DELISTED
bluebird bio
BLUE
$287K 0.12%
511
+140
+38% +$88.7K
SWTX
232
DELISTED
SpringWorks Therapeutics
SWTX
$286K 0.12%
3,940
-3,228
-45% -$208K
FPRX
233
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$286K 0.12%
+16,810
New +$211K
ARQT icon
234
Arcutis Biotherapeutics
ARQT
$3.48B
$285K 0.12%
10,117
-1,964
-16% -$48.1K
AMTI
235
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$285K 0.12%
+9,263
New +$294K
KRRO icon
236
Korro Bio
KRRO
$145M
$284K 0.12%
161
-148
-48% -$195K
MGNX icon
237
MacroGenics
MGNX
$233M
$284K 0.12%
12,419
-2,965
-19% -$68.3K
PTGX icon
238
Protagonist Therapeutics
PTGX
$8.55B
$284K 0.12%
14,102
-4,946
-26% -$106K
RNAC icon
239
Cartesian Therapeutics
RNAC
$218M
$284K 0.12%
3,122
-712
-19% -$61.7K
TPTX
240
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$284K 0.12%
2,333
-2,701
-54% -$296K
CLDX icon
241
Celldex Therapeutics
CLDX
$2.94B
$283K 0.12%
+16,174
New +$291K
BCEL
242
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$283K 0.12%
17,550
-129
-0.7% -$1.93K
RLMD icon
243
Relmada Therapeutics
RLMD
$540M
$282K 0.12%
8,783
+2,219
+34% +$76.3K
KLRS
244
Kalaris Therapeutics
KLRS
$80.9M
$282K 0.12%
+319
New +$245K
RLAY icon
245
Relay Therapeutics
RLAY
$4B
$280K 0.12%
+6,732
New +$304K
XNCR icon
246
Xencor
XNCR
$1.45B
$280K 0.12%
6,426
-4,407
-41% -$182K
ORTX
247
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$280K 0.12%
6,484
+2,455
+61% +$110K
ORIC icon
248
Oric Pharmaceuticals
ORIC
$1.17B
$279K 0.12%
+8,247
New +$237K
FATE icon
249
Fate Therapeutics
FATE
$275M
$278K 0.12%
3,061
-6,967
-69% -$433K
IMVT icon
250
Immunovant
IMVT
$7.93B
$278K 0.12%
+6,028
New +$279K
8 9
10
11 12

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2020 Portfolio in Review

As of Q4 2020, Virtus ETF Advisers held 372 positions worth $241M, up 26% from $191M the previous quarter. Its ten largest holdings account for 9.4% of the portfolio.

Virtus ETF Advisers deployed $11.8M of net new capital in Q4 2020, opening 47 new positions and adding to 146 existing holdings. Its largest new stake was Harmony Biosciences: 14,899 shares worth $539K.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 32% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $572K trimmed.

  • Virtus ETF Advisers's largest Q4 2020 buy was Harmony Biosciences: 14,899 shares worth $539K.
  • Virtus ETF Advisers added most to Brookfield Renewable in Q4 2020, an estimated $1.51M increase.
  • Virtus ETF Advisers's biggest Q4 2020 reduction was Amicus Therapeutics, cutting an estimated $572K.
  • Virtus ETF Advisers fully exited Immunomedics Inc in Q4 2020, selling an estimated $1.61M.
  • Virtus ETF Advisers's ten largest holdings make up 9.4% of its $241M portfolio in Q4 2020.
  • Virtus ETF Advisers opened 47 new positions and closed 17 in Q4 2020.
  • Virtus ETF Advisers's portfolio value rose 26% quarter-over-quarter to $241M.

Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.